FDA commissioner Gottlieb resigns despite record success

By Maggie Lynch

- Last updated on GMT

(Image: US FDA)
(Image: US FDA)

Related tags: Fda, Scott Gottlieb

US FDA commissioner Scott Gottlieb resigns two years into the role, after pushing for regulations on tobacco, e-cigarettes, and opioids.

The Food and Drug Administration (FDA) will see a change in leadership as commissioner, Scott Gottlieb, leaves the helm of the agency next month, despite presiding over a period that saw record drug approvals and increased communication to stakeholders.

According to the Washington Post​, in his resignation letter, given to Health and Human Services Secretary, Alex Azar, Gottlieb stated he is resigning to spend more time with his family, after commuting to Washington, D.C. from Westport, CT.

Gottlieb handed in his resignation two months after he publicly denied reports that he was planning to step down.

Gottlieb handed in his resignation on Tuesday, after publically criticizing the drugstore chain Walgreens Monday for selling tobacco products to minors, “the company’s stores have racked up almost 1,800 violations across the country,”​ he said in a statement​.

In April, Gottlieb told CNN that while opioids are the biggest crisis​ facing the FDA, tobacco and e-cigarette use among teenagers could be deemed an epidemic. He has taken actions on both ‘epidemics’ approving therapies for opioid withdrawal​, cracking down on opioid manufacturers​, and working to pass guidances on e-cigarette usage.

President Donald Trump appointed Gottlieb to the position of commissioner in May 2017. Following the news of his resignation, Trump tweeted:

While Gottlieb led the FDA in 2018​, the agency approved or tentatively approved 1,021 abbreviated new drug applications, published more than 250 new or revised guidances​, launched an online function for controlled correspondence and responded to 700 inquiries, and issued 2,659 complete response letters.

Notably, 2018 was a record year for drug approvals with 59 novel drugs and biologics approved in the course of the year, which improved upon the previous record of 53 approvals in 1996.

Additionally, in 2018, the FDA approved the first generics for Suboxone, EpiPen, Zortress, Copaxone, and Brilinta, with Gottlieb often emphasizing the potential for generics to improve patients’ access to affordable drugs and releasing a draft guidance for generic competition​.

Related topics: Markets & Regulations, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Follow us


View more